Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

The debate continues over whether some prostate cancers should be called “cancer.” (University of California San Francisco)

Delayed treatment related to the diagnostic workup of lung nodules correlated with worse survival in stage I non-small cell lung cancer. (Radiology)

Multiple recent market withdrawals of drugs that received FDA accelerated approvals have raised concern about the approval process. (BioSpace)

The FDA expanded indications for asciminib (Scemblix) with an accelerated approval for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

And FDA expanded indications for oral liquid methotrexate (Jylamvo) to include pediatric acute lymphoblastic leukemia, Shorla Oncology announced.

New insights into how burn scars evolve into the aggressive skin cancer Marjolin’s ulcer. (University of Calgary)

GlycoMimetics announced that a phase II/III trial of the E-selectin antagonist uproleselan plus cytarabine/daunorubicin in newly diagnosed acute myeloid leukemia did not meet the primary endpoint of event-free survival.

A shift in the decision-making process, lagging participation in clinical trials, continuing burden of financial toxicity — a few of the findings from a new survey of cancer survivors. (National Coalition for Cancer Survivorship)

Closer scrutiny of the evidence suggesting the diabetes drug metformin has anticancer activity. (Oncology News Central)

A Texas doctor received a 10-year prison sentence and was ordered to pay $34 million in restitution for his part in a Medicare scam that involved prescribing durable medical equipment and cancer genetics tests for patients he had never met, the Justice Department announced.

A Michigan physician has been charged with a multimillion-dollar scheme involving illegal diversion and sale of cancer drugs, the U.S. Attorney’s Office for the Eastern District of Michigan announced.

Aided by artificial intelligence, a review of almost 10,000 prostate cancer patients enrolled in clinical trials showed misclassification of risk status in 42% of cases. (JCO Precision Oncology)

The Biden administration announced another $6 million in grants to support the Cancer Moonshot program in cancer prevention, treatment, and diagnosis.

Please enable JavaScript to view the

comments powered by Disqus.